{"protocolSection": {"identificationModule": {"nctId": "NCT00313313", "orgStudyIdInfo": {"id": "CV181-040"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas", "officialTitle": "A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-04"}, "primaryCompletionDateStruct": {"date": "2007-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-04-10", "studyFirstSubmitQcDate": "2006-04-11", "studyFirstPostDateStruct": {"date": "2006-04-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-17", "resultsFirstSubmitQcDate": "2009-08-17", "resultsFirstPostDateStruct": {"date": "2009-09-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-14", "lastUpdatePostDateStruct": {"date": "2015-05-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes", "detailedDescription": "All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control (defined as rescue) will be eligible to enter the long-term treatment extension period where they will receive metformin.Rescue treatment with metformin is also available during the long-term extension period for subjects who meet glycemic criteria."}, "conditionsModule": {"conditions": ["Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 768, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)", "type": "EXPERIMENTAL", "description": "Metformin 500-2500 mg (as needed)", "interventionNames": ["Drug: Saxagliptin", "Drug: Glyburide", "Drug: Metformin"]}, {"label": "Saxagliptin 5 mg + Glyburide 7.5 mg (B)", "type": "EXPERIMENTAL", "description": "Metformin 500-2500 mg (as needed)", "interventionNames": ["Drug: Saxagliptin", "Drug: Glyburide", "Drug: Metformin"]}, {"label": "Placebo + Glyburide 7.5 mg (C)", "type": "PLACEBO_COMPARATOR", "description": "Metformin 500-2500 mg (as needed)", "interventionNames": ["Drug: Placebo", "Drug: Glyburide", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \\[ST\\], 12 months long-term \\[LT\\])", "armGroupLabels": ["Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).", "armGroupLabels": ["Saxagliptin 5 mg + Glyburide 7.5 mg (B)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Glyburide", "description": "Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)", "armGroupLabels": ["Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)", "Saxagliptin 5 mg + Glyburide 7.5 mg (B)"]}, {"type": "DRUG", "name": "Placebo", "description": "Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)", "armGroupLabels": ["Placebo + Glyburide 7.5 mg (C)"]}, {"type": "DRUG", "name": "Glyburide", "description": "Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)", "armGroupLabels": ["Placebo + Glyburide 7.5 mg (C)"]}, {"type": "DRUG", "name": "Metformin", "description": "Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)", "armGroupLabels": ["Placebo + Glyburide 7.5 mg (C)", "Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)", "Saxagliptin 5 mg + Glyburide 7.5 mg (B)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (A1C) at Week 24", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Participants Achieving A1C < 7% at Week 24", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus glyburide versus placebo plus upward titrated glyburide at Week 24.", "timeFrame": "Week 24"}, {"measure": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline values.", "timeFrame": "Baseline, Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 Diabetes.\n* Treated with a sulfonylurea for at least 2 months.\n* Inadequate blood sugar control.\n* Are not on any other medications to lower blood sugar.\n* No major heart, liver or kidney problems.\n* Women not pregnant or breast feeding.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Reserach Solutions, Llc", "city": "Jonesboro", "state": "Arkansas", "zip": "72401", "country": "United States", "geoPoint": {"lat": 35.8423, "lon": -90.70428}}, {"facility": "Searcy Medical Center", "city": "Searcy", "state": "Arkansas", "zip": "72143", "country": "United States", "geoPoint": {"lat": 35.25064, "lon": -91.73625}}, {"facility": "Stewart Medical Group", "city": "Alhambra", "state": "California", "zip": "91801", "country": "United States", "geoPoint": {"lat": 34.09529, "lon": -118.12701}}, {"facility": "Southland Clinical Research Center, Inc.", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Valley Research", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Randall Shue, D.O.", "city": "Los Angeles", "state": "California", "zip": "90023", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Clinical Trials Research", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "New West Physicians", "city": "Golden", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.75554, "lon": -105.2211}}, {"facility": "Phoenix Internal Medicine Associates, Llc", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Christiana Care Research Institute", "city": "Newark", "state": "Delaware", "zip": "19713", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Central Florida Clinical Trials", "city": "Altamonte Springs", "state": "Florida", "zip": "32714", "country": "United States", "geoPoint": {"lat": 28.66111, "lon": -81.36562}}, {"facility": "Family Care Assoc & Emerald Care Res Grp", "city": "Chipley", "state": "Florida", "zip": "32428", "country": "United States", "geoPoint": {"lat": 30.78186, "lon": -85.53854}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Fpa Clinical Research", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Emerald Coast Research Group", "city": "Marianna", "state": "Florida", "zip": "32446", "country": "United States", "geoPoint": {"lat": 30.77436, "lon": -85.22687}}, {"facility": "University Of Miami Diabetes Research Inst.", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Atlanta Pharmaceutical Research Center, Inc", "city": "Dunwoody", "state": "Georgia", "zip": "30338", "country": "United States", "geoPoint": {"lat": 33.94621, "lon": -84.33465}}, {"facility": "Cedar-Crosse Research Ctr", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Family Medical Center Of Hart Co.", "city": "Munfordville", "state": "Kentucky", "zip": "42765", "country": "United States", "geoPoint": {"lat": 37.27228, "lon": -85.89108}}, {"facility": "Columbia Medical Practice", "city": "Columbia", "state": "Maryland", "zip": "21045", "country": "United States", "geoPoint": {"lat": 39.24038, "lon": -76.83942}}, {"facility": "Va Medical Center", "city": "Kansas City", "state": "Missouri", "zip": "64128", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "St. Louis Center For Clinical Research", "city": "St. Louis", "state": "Missouri", "zip": "63128", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Nevada Alliance Against Diabetes", "city": "North Las Vegas", "state": "Nevada", "zip": "89030", "country": "United States", "geoPoint": {"lat": 36.19886, "lon": -115.1175}}, {"facility": "Physicians Research Center", "city": "Toms River", "state": "New Jersey", "zip": "08755", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Cny Family Care", "city": "East Syracuse", "state": "New York", "zip": "13057", "country": "United States", "geoPoint": {"lat": 43.06534, "lon": -76.07853}}, {"facility": "Metrolina Internal Medicine", "city": "Charlotte", "state": "North Carolina", "zip": "28204", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Med Res Assoc Charlotte", "city": "Charlotte", "state": "North Carolina", "zip": "28211", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Regional Physicians Research", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Diabetes & Endocrinology Consultants, Pc", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Mountain Top Clinical Research Center", "city": "Sparta", "state": "North Carolina", "zip": "28675", "country": "United States", "geoPoint": {"lat": 36.50541, "lon": -81.12092}}, {"facility": "Daystar Clinical Research, Inc.", "city": "Akron", "state": "Ohio", "zip": "44313", "country": "United States", "geoPoint": {"lat": 41.08144, "lon": -81.51901}}, {"facility": "Community Health Care", "city": "Canal Fulton", "state": "Ohio", "zip": "44614", "country": "United States", "geoPoint": {"lat": 40.88978, "lon": -81.59762}}, {"facility": "Triphase Research, Ltd.", "city": "Franklin", "state": "Ohio", "zip": "45005", "country": "United States", "geoPoint": {"lat": 39.55895, "lon": -84.30411}}, {"facility": "Albert J Weisbrot,Md&Assoc Inc", "city": "Mason", "state": "Ohio", "zip": "45040", "country": "United States", "geoPoint": {"lat": 39.36006, "lon": -84.30994}}, {"facility": "Dr Bahagwan Dass Md", "city": "Youngstown", "state": "Ohio", "zip": "44507", "country": "United States", "geoPoint": {"lat": 41.09978, "lon": -80.64952}}, {"facility": "Oklahoma Cardiovascular And Hypertension Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73132", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Utica Park Clinic", "city": "Tulsa", "state": "Oklahoma", "zip": "74104", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Integris Family Care Yukon", "city": "Yukon", "state": "Oklahoma", "zip": "73109", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"facility": "Coordinators Plus, Llc", "city": "Eugene", "state": "Oregon", "zip": "97401", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Oregon Clinical Research", "city": "Portland", "state": "Oregon", "zip": "97220", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Pearl Clinical Research", "city": "Norristown", "state": "Pennsylvania", "zip": "19401", "country": "United States", "geoPoint": {"lat": 40.1215, "lon": -75.3399}}, {"facility": "Banksville Medical Pc", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15216", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Guthrie Clinic, Ltd", "city": "Sayre", "state": "Pennsylvania", "zip": "18840", "country": "United States", "geoPoint": {"lat": 41.97896, "lon": -76.5155}}, {"facility": "Upstate Pharmaceutical Research", "city": "Simsonville", "state": "South Carolina", "zip": "29681", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "Spartanburg Medical Research", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Southeastern Research Assoc", "city": "Taylors", "state": "South Carolina", "zip": "29687", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"facility": "Capital Medical Clinic, Llp", "city": "Austin", "state": "Texas", "zip": "78705", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Texas Center For Drug Development, P.A.", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Breath Of Life Research Institute", "city": "Katy", "state": "Texas", "zip": "77450", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"facility": "Diabetes & Glandular Disease Research Assoc, Pa", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "S.A.M. Clinical Research Center", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Tidewater Integrated Medical Research", "city": "Virginia Beach", "state": "Virginia", "zip": "23451", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"facility": "Office Of Dr. Gray", "city": "Spokane", "state": "Washington", "zip": "99216", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Advanced Healthcare S.C.", "city": "Milwaukee", "state": "Wisconsin", "zip": "53209", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Local Institution", "city": "Mar Del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1406FEQ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1425AGC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Local Institution", "city": "B. Rodolfo Teofilo", "state": "Ceara", "zip": "60430", "country": "Brazil"}, {"facility": "Local Institution", "city": "Fortaleza", "state": "Ceara", "zip": "60021", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "Local Institution", "city": "Belo Horizonte", "state": "Minas Gerais", "zip": "30150", "country": "Brazil", "geoPoint": {"lat": -19.92083, "lon": -43.93778}}, {"facility": "Local Institution", "city": "Belem", "state": "Para", "zip": "66073", "country": "Brazil", "geoPoint": {"lat": -1.45583, "lon": -48.50444}}, {"facility": "Local Institution", "city": "Porto Alegre", "state": "Rio Grande Do Sul", "zip": "90035003", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Local Institution", "city": "Porto Alegre", "state": "Rio Grande Do Sul", "zip": "90610", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Local Institution", "city": "Campinas", "state": "Sao Paulo", "zip": "13059", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"facility": "Local Institution", "city": "Mar\u00edlia", "state": "Sao Paulo", "zip": "17519", "country": "Brazil", "geoPoint": {"lat": -22.21389, "lon": -49.94583}}, {"facility": "Local Institution", "city": "Sao Paulo - Sp", "state": "Sao Paulo", "zip": "04231", "country": "Brazil"}, {"facility": "Local Institution", "city": "Vila Mariana", "state": "Sao Paulo", "zip": "04020", "country": "Brazil", "geoPoint": {"lat": -23.58333, "lon": -46.63333}}, {"facility": "Local Institution", "city": "Hong Kong", "zip": "SAR", "country": "Hong Kong", "geoPoint": {"lat": 22.27832, "lon": 114.17469}}, {"facility": "Local Institution", "city": "Kowloon", "country": "Hong Kong", "geoPoint": {"lat": 22.31667, "lon": 114.18333}}, {"facility": "Local Institution", "city": "Givatayim", "zip": "53583", "country": "Israel", "geoPoint": {"lat": 32.07225, "lon": 34.81253}}, {"facility": "Local Institution", "city": "Haifa", "zip": "31096", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Local Institution", "city": "Holon", "zip": "58100", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "Local Institution", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Local Institution", "city": "Rishon Le-Zion", "zip": "75650", "country": "Israel", "geoPoint": {"lat": 31.97102, "lon": 34.78939}}, {"facility": "Local Institution", "city": "Tel Aviv", "zip": "64353", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"facility": "Local Institution", "city": "Zefat", "zip": "13100", "country": "Israel", "geoPoint": {"lat": 32.96465, "lon": 35.496}}, {"facility": "Local Institution", "city": "Zerifin", "zip": "70300", "country": "Israel", "geoPoint": {"lat": 31.95857, "lon": 4.83723}}, {"facility": "Local Institution", "city": "Kyunggi-Do", "zip": "420-717", "country": "Korea, Republic of"}, {"facility": "Local Institution", "city": "Kyunggi-Do", "zip": "463-707", "country": "Korea, Republic of"}, {"facility": "Local Institution", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "130-702", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "135-710", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "135-720", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Seoul", "zip": "137040", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Local Institution", "city": "Suwon", "zip": "443721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Local Institution", "city": "Tijuana, B.C.", "state": "Baja California", "zip": "22320", "country": "Mexico"}, {"facility": "Local Institution", "city": "Df", "state": "Distrito Federal", "zip": "11800", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44340", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Cuernavaca", "state": "Morelos", "zip": "62250", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64060", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64710", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Merida", "state": "Yucatan", "zip": "97210", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Local Institution", "city": "Durango", "zip": "64710", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Local Institution", "city": "San Isidro", "state": "Lima", "zip": "27", "country": "Peru", "geoPoint": {"lat": -12.11667, "lon": -77.05}}, {"facility": "Local Institution", "city": "Lima", "zip": "18", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Local Institution", "city": "Lima", "zip": "LIMA 1", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Local Institution", "city": "Lima", "zip": "LIMA 31", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Local Institution", "city": "Cebu", "zip": "6000", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Local Institution", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Local Institution", "city": "Quezon", "zip": "1102", "country": "Philippines", "geoPoint": {"lat": 7.73028, "lon": 125.09889}}, {"facility": "Local Institution", "city": "Carolina", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"facility": "Local Institution", "city": "Guaynabo", "zip": "00966", "country": "Puerto Rico", "geoPoint": {"lat": 18.35745, "lon": -66.111}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00717", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Singapore", "zip": "119074", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Local Institution", "city": "Umhlanga Rocks", "state": "Kwa Zulu Natal", "zip": "4319", "country": "South Africa"}, {"facility": "Local Institution", "city": "Kimberley", "state": "Northern Cape", "zip": "8301", "country": "South Africa", "geoPoint": {"lat": -28.73226, "lon": 24.76232}}, {"facility": "Local Institution", "city": "Tygerberg", "state": "Western Cape", "zip": "7505", "country": "South Africa"}, {"facility": "Local Institution", "city": "Cape Town", "zip": "7008", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Local Institution", "city": "Johannesburg", "zip": "2196", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Local Institution", "city": "Changhua", "zip": "500", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "Local Institution", "city": "Taichung", "zip": "402", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Local Institution", "city": "Taipei", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}, "referencesModule": {"references": [{"pmid": "19614786", "type": "BACKGROUND", "citation": "Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009 Sep;63(9):1395-406. doi: 10.1111/j.1742-1241.2009.02143.x. Epub 2009 Jul 15. Erratum In: Int J Clin Pract. 2010 Jan;64(2):277."}, {"pmid": "27402391", "type": "DERIVED", "citation": "Perl S, Cook W, Wei C, Iqbal N, Hirshberg B. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. Diabetes Ther. 2016 Sep;7(3):527-35. doi: 10.1007/s13300-016-0184-9. Epub 2016 Jul 11."}, {"pmid": "27033025", "type": "DERIVED", "citation": "Bonora E, Bryzinski B, Hirshberg B, Cook W. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutr Metab Cardiovasc Dis. 2016 May;26(5):374-9. doi: 10.1016/j.numecd.2015.11.004. Epub 2015 Dec 1."}, {"pmid": "23795975", "type": "DERIVED", "citation": "Karyekar CS, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract. 2013 Aug;67(8):759-67. doi: 10.1111/ijcp.12212. Epub 2013 Jun 24."}, {"pmid": "21680990", "type": "DERIVED", "citation": "Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med. 2011 Jul;123(4):63-70. doi: 10.3810/pgm.2011.07.2305."}, {"pmid": "21562067", "type": "DERIVED", "citation": "Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011 Apr;8(2):150-9. doi: 10.1177/1479164111404574."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "FG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "FG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "248"}, {"groupId": "FG001", "numSubjects": "253"}, {"groupId": "FG002", "numSubjects": "267"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "61 subjects completed the study without being rescued", "numSubjects": "185"}, {"groupId": "FG001", "comment": "55 subjects completed the study without being rescued", "numSubjects": "187"}, {"groupId": "FG002", "comment": "26 subjects completed the study without being rescued", "numSubjects": "185"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "63"}, {"groupId": "FG001", "numSubjects": "66"}, {"groupId": "FG002", "numSubjects": "82"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "20"}]}, {"type": "Withdrawal of consent by subject", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "31"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Poor/Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Subject No Longer Meets Study Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "BG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "BG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "248"}, {"groupId": "BG001", "value": "253"}, {"groupId": "BG002", "value": "267"}, {"groupId": "BG003", "value": "768"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.36", "spread": "9.58"}, {"groupId": "BG001", "value": "54.85", "spread": "9.96"}, {"groupId": "BG002", "value": "55.06", "spread": "10.69"}, {"groupId": "BG003", "value": "55.09", "spread": "10.09"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "143"}, {"groupId": "BG002", "value": "144"}, {"groupId": "BG003", "value": "422"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "113"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "123"}, {"groupId": "BG003", "value": "346"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (A1C) at Week 24", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 Last Observation Carried Forward (LOCF), participants must have had a baseline and at least 1 post-baseline measurement. If participant received rescue medication, measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "246"}, {"groupId": "OG001", "value": "250"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.36", "spread": "0.057"}, {"groupId": "OG001", "value": "8.48", "spread": "0.056"}, {"groupId": "OG002", "value": "8.44", "spread": "0.055"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.83", "spread": "0.074"}, {"groupId": "OG001", "value": "7.83", "spread": "0.074"}, {"groupId": "OG002", "value": "8.52", "spread": "0.077"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "0.059"}, {"groupId": "OG001", "value": "-0.64", "spread": "0.059"}, {"groupId": "OG002", "value": "0.08", "spread": "0.057"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "247"}, {"groupId": "OG001", "value": "252"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "170.1", "spread": "2.67"}, {"groupId": "OG001", "value": "175.0", "spread": "2.79"}, {"groupId": "OG002", "value": "174.4", "spread": "2.64"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.4", "spread": "2.76"}, {"groupId": "OG001", "value": "164.6", "spread": "2.76"}, {"groupId": "OG002", "value": "174.6", "spread": "2.93"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "2.42"}, {"groupId": "OG001", "value": "-9.7", "spread": "2.39"}, {"groupId": "OG002", "value": "0.7", "spread": "2.33"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C < 7% at Week 24", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus glyburide versus placebo plus upward titrated glyburide at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "246"}, {"groupId": "OG001", "value": "250"}, {"groupId": "OG002", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.4"}, {"groupId": "OG001", "value": "22.8"}, {"groupId": "OG002", "value": "9.1"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline values.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg*min/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG001", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator."}, {"id": "OG002", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "190"}, {"groupId": "OG001", "value": "195"}, {"groupId": "OG002", "value": "204"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "49124", "spread": "677.2"}, {"groupId": "OG001", "value": "50342", "spread": "669.0"}, {"groupId": "OG002", "value": "51801", "spread": "656.9"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "45402", "spread": "681.5"}, {"groupId": "OG001", "value": "45391", "spread": "699.3"}, {"groupId": "OG002", "value": "52416", "spread": "703.7"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4296", "spread": "595.0"}, {"groupId": "OG001", "value": "-5000", "spread": "585.5"}, {"groupId": "OG002", "value": "1196", "spread": "574.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo + Glyburide 7.5 mg", "description": "The Placebo + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded placebo oral tablets, blinded glyburide 2.5 mg, and open-label glyburide 7.5 mg once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator. Blinded glyburide may have been uptitrated by 5 mg according to glycemic criteria provided it had not been previously down-titrated.", "seriousNumAffected": 23, "seriousNumAtRisk": 267, "otherNumAffected": 163, "otherNumAtRisk": 267}, {"id": "EG001", "title": "Saxagliptin 2.5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 2.5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 2.5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator.", "seriousNumAffected": 18, "seriousNumAtRisk": 248, "otherNumAffected": 144, "otherNumAtRisk": 248}, {"id": "EG002", "title": "Saxagliptin 5 mg + Glyburide 7.5 mg", "description": "The Saxagliptin 5 mg + Glyburide 7.5 mg group includes data from subjects randomized to receive coadministration of blinded saxagliptin 5 mg oral tablets and open-label glyburide 7.5 mg oral tables once daily. Open-label glyburide may have been down titrated by 2.5 mg once due to hypoglycemia as deemed necessary by the investigator.", "seriousNumAffected": 12, "seriousNumAtRisk": 253, "otherNumAffected": 154, "otherNumAtRisk": 253}], "seriousEvents": [{"term": "ANGINA PECTORIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CARDIOGENIC SHOCK", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "MYOCARDIAL ISCHAEMIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "ATRIOVENTRICULAR BLOCK COMPLETE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "EXTREMITY NECROSIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "PERIPHERAL VASCULAR DISORDER", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CHOLECYSTITIS ACUTE", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 253}]}, {"term": "SYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "HAEMORRHAGIC STROKE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CEREBROVASCULAR ACCIDENT", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "ASCITES", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "UMBILICAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "SALIVARY GLAND MASS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "UPPER GASTROINTESTINAL HAEMORRHAGE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "VERTIGO", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "PYELONEPHRITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "VIRAL INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "WOUND INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CELLULITIS ORBITAL", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "HYPOGLYCAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "LOWER LIMB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "POST-TRAUMATIC PAIN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "ROAD TRAFFIC ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "GASTROINTESTINAL INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "OSTEOARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "HAEMOPTYSIS", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}, {"term": "BRONCHITIS CHRONIC", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "ASTHENIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "SUDDEN CARDIAC DEATH", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "ADENOMA BENIGN", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "GASTRIC CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "PROSTATE CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "THYROID NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 253}]}, {"term": "MYELODYSPLASTIC SYNDROME", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 253}]}], "otherEvents": [{"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 23, "numAtRisk": 253}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 25, "numAtRisk": 253}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 253}]}, {"term": "DYSPEPSIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 253}]}, {"term": "GASTRITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 253}]}, {"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 253}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 253}]}, {"term": "PHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 253}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 253}]}, {"term": "PHARYNGOTONSILLITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 253}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 32, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 42, "numAtRisk": 253}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 253}]}, {"term": "DYSLIPIDAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 253}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 253}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 253}]}, {"term": "PAIN IN EXTREMITY", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 253}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 267}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 248}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 253}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Thailand"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}, {"id": "D000005905", "term": "Glyburide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M9017", "name": "Glyburide", "asFound": "Lumefantrine", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}